WAG that was an uncomfortable reality check that made me go do a little research. In our phase 2 we looked at 82 patients with 12 sites and screening/recruitment did not seem to take that long, a few months from memory.
In this we have double the number of people to recruit/screen from an eventual 16 sites. You would imagine most previous participants would be keen if they don't have commitments elsewhere and if the original 12 sites are part of the 16 (I didn't check). This should provide a strong base for recruitment you would think (unless they also need to be fully screened again - I have no idea how these things work)
Maybe someone with a clue like @hottod could comment but 12-18 months seems a ridiculously long time given the phase 2 managed it in much shorter time (albeit with half the patient numbers and shorter commitment required).
- Forums
- ASX - By Stock
- NEU
- Ann: Phase 3 trial of trofinetide in Rett syndrome commences
NEU
neuren pharmaceuticals limited
Add to My Watchlist
6.14%
!
$13.31

Ann: Phase 3 trial of trofinetide in Rett syndrome commences, page-22
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.31 |
Change
0.770(6.14%) |
Mkt cap ! $1.655B |
Open | High | Low | Value | Volume |
$12.96 | $14.00 | $12.91 | $19.76M | 1.453M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3000 | $13.30 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.33 | 3716 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3000 | 13.300 |
2 | 10200 | 13.200 |
1 | 2500 | 13.190 |
2 | 1750 | 13.180 |
1 | 50 | 13.170 |
Price($) | Vol. | No. |
---|---|---|
13.330 | 3716 | 1 |
13.370 | 3716 | 1 |
13.390 | 600 | 1 |
13.400 | 3783 | 2 |
13.430 | 3716 | 1 |
Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online